Corvus Pharmaceuticals, Inc. (NasdaqGM: CRVS)
Health Care · Biotechnology · US
$10.52
-3.49% today · +48.0% 1Y
Corvus Pharmaceuticals, Inc. (NasdaqGM: CRVS) operates in the Biotechnology industry within the Health Care sector. The company is valued at $884.95M and employs 37 people.
Over the last twelve months the share price has gained 48.0%, trading between 6.39 and 26.95.
Tweenvest scores Corvus Pharmaceuticals, Inc. across four factors: quality 35/100, value 78/100. Its strongest factor is value.
CRVS price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $884.95M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.62
- Dividend yield
- —
- Beta (5Y)
- 1.43
- 52-week high
- $26.95
- 52-week low
- $6.39
- Avg volume (3M)
- —
- Shares outstanding
- 84.12M
- Employees
- 37
- Next earnings
- —
About Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in the development and commercialization of immuno-oncology therapies. Their leading investigational compound, Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, is currently progressing through Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and head and neck cancers. Another promising candidate, CPI-818, functions as a covalent ITK inhibitor. This therapy is undergoing Phase I/Ib clinical evaluation for patients battling various malignant T-cell lymphomas, aiming to impede the proliferation of specific malignant T-cells. Additionally, Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor, is in Phase II clinical trials for individuals diagnosed with either advanced or refractory renal cell carcinoma. Beyond these clinical-stage assets, Corvus maintains a preclinical portfolio including CPI-182, an antibody designed to block inflammation and myeloid suppression, and CPI-935, an adenosine A2B receptor antagonist intended to prevent fibrosis. The company also benefits from a strategic collaboration with Angel Pharmaceuticals, which aids in advancing its diverse pipeline of targeted experimental drugs. Founded in 2014, Corvus Pharmaceuticals is headquartered in Burlingame, California.
- ISIN
- US2210151005
- Founded
- 2014
- Listed since
- Mar 23, 2016
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Jade Biosciences, Inc.NasdaqCM: JBIO | $915.17M | $14.39 | +1.91% |
| Odyssey Therapeutics, Inc.NasdaqCM: ODTX | $910.45M | $19.00 | -8.32% |
| Alphamab OncologySEHK: 9966 | $907.71M | HK$7.36 | -11.44% |
| Frontier Biotechnologies Inc.SHSE: 688221 | $886.38M | CN¥15.85 | -6.05% |
| Beijing SL Pharmaceutical Co., Ltd.SZSE: 002038 | $883.46M | CN¥5.76 | +0.17% |
| Monte Rosa Therapeutics, Inc.NasdaqGS: GLUE | $878.73M | $10.30 | -0.19% |
| Lepu Biopharma Co., Ltd.SEHK: 2157 | $878.35M | HK$3.82 | -5.56% |
| Kuros Biosciences AGSWX: KURN | $878.10M | CHF18.35 | -1.50% |
Figures last refreshed Oct 11, 2026.